Cassava Sciences | PTIE - Net Income


Cassava Sciences reported $-10.81M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
Abbott USD 1.78B 132M Dec/2025
Amgen USD 1.33B 1.88B Dec/2025
Biogen USD 466.5M 168.3M Sep/2025
Cara Therapeutics USD -4.91M 2.77M Mar/2025
Cassava Sciences USD -10.81M 33.41M Sep/2025
Eisai JPY 17.18B 7.02B Dec/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Geron USD -31.14M 12.72M Dec/2025
J&J USD 5.12B 36M Dec/2025
Merck USD 2.96B 2.82B Dec/2025
Novartis USD 3.93B 96M Sep/2025
Novavax USD -121.3M 283.68M Sep/2024
Pfizer USD -1.65B 5.19B Dec/2025
Roche Holding CHF 5.47B 1.76B Dec/2025